-
Amazon to ship stuff for any business, not just its own merchants
-
Swastikas daubed on NY Jewish homes, synagogues: police
-
Passengers stranded on cruise off Cape Verde following suspected virus deaths
-
Colombian guerrillas offer peace talks with Petro successor
-
Britney Spears admits reckless driving in plea deal
-
Health emergency on the MV Hondius: what we know
-
US downs Iran missiles and drones, destroys six of Tehran's boats
-
Simeone laughs off 'cheaper' Atletico hotel switch before Arsenal clash
-
Rohit, Rickelton keep Mumbai in the hunt
-
What is hantavirus, and can it spread between humans?
-
Britney Spears admits to reckless driving in plea deal
-
Two dead as car ploughs into crowd in Germany's Leipzig
-
Ujiri hired as president of NBA's Mavericks
-
McFarlane backs Chelsea flops after woeful Forest defeat
-
Demi Moore joins Cannes Festival jury
-
Two dead after car ploughs into people in Germany's Leipzig: mayor
-
China's Wu holds slender lead in World Snooker Championship final
-
Mosley fired as coach after Magic's first-round NBA playoff exit
-
Stars set for Met Gala, fashion's biggest night
-
Forest sink woeful Chelsea to boost survival bid
-
Oil prices jump as Iran attacks UAE, US warships enter Hormuz
-
France launches one-euro university meals for all students
-
French TV defend Champions Cup video referee after Van Graan criticism
-
Former France, England duo called up by Fiji for Nations Championship
-
US Supreme Court temporarily restores mail access to abortion pill
-
3 dead in Colombia monster truck show crash
-
Mysterious world beyond Pluto may have an atmosphere: astronomers
-
UniCredit raises capital ahead of Commerzbank takeover bid
-
A year into Merz government, German far right stronger than ever
-
French scholars seek to resurrect Moliere with AI play
-
Allies jolted on defence as Trump pulls troops from Germany
-
Passengers isolating on cruise after Cape Verde ban over suspected virus deaths
-
Famed cartoonist Chappatte calls medium a 'barometer' of freedom
-
Three things we learned from the Miami Grand Prix
-
Energy crisis fuels calls to cut methane emissions
-
Europe, Canada pull together in Yerevan in Trump's shadow
-
India's Modi eyes important win in opposition-held West Bengal
-
Hantavirus: spread by rodents, potentially fatal, with no specific cure
-
French starlet Seixas to ride Tour de France in July
-
Cruise ship operator says Dutch to repatriate two ill passengers
-
India's Modi eyes win in opposition-held West Bengal
-
In Wales, UK Labour Party loses grip on storied heartland
-
Musk vs OpenAI trial enters second week
-
India's Modi faces key test as vote count underway
-
Japan PM says oil crisis has 'enormous impact' in Asia-Pacific
-
Badminton no.1 An brings 'fire' as South Korea win Uber Cup
-
Saka sparks Arsenal attack into life ahead of Atletico showdown
-
Atletico aim to show Alvarez their ambition in Arsenal semi
-
Seoul, Taipei hit records as Asian stocks track Wall St tech rally
-
Boeing faces civil trial over 737 MAX crash
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
N.Fournier--BTB